tiprankstipranks

Camp4 Therapeutics initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of Camp4 Therapeutics (CAMP) with an Overweight rating and $18 price target The company is is pioneering development of regulatory RNAs as a novel therapeutic modality, the analyst tells investors in a research note. The firm estimates Camp4 holds pro forma cash of $79M to fund operations into Q2 of 2026.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue